Immunocore Holdings PLC IMCR.OQ IMCR.O is expected to show a rise in quarterly revenue when it reports results on August 7 for the period ending June 30 2025
The Abingdon Oxfordshire-based company is expected to report a 25.8% increase in revenue to $94.772 million from $75.35 million a year ago, according to the mean estimate from 15 analysts, based on LSEG data.
LSEG's mean analyst estimate for Immunocore Holdings PLC is for a loss of 21 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Immunocore Holdings PLC is $66.00, about 50.7% above its last closing price of $32.53
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.37 | -0.39 | 0.10 | Beat | 125.7 |
Dec. 31 2025 | -0.29 | -0.26 | -0.47 | Missed | -83 |
Sep. 30 2024 | -0.35 | -0.35 | 0.17 | Beat | 148.4 |
Jun. 30 2024 | -0.55 | -0.48 | -0.23 | Beat | 51.7 |
Mar. 31 2024 | -0.38 | -0.36 | -0.49 | Missed | -35.4 |
Dec. 31 2023 | -0.28 | -0.28 | -0.40 | Missed | -47 |
Sep. 30 2023 | -0.35 | -0.35 | 0.05 | Beat | 113.8 |
Jun. 30 2023 | -0.40 | -0.41 | -0.36 | Beat | 9.7 |
This summary was machine generated August 5 at 09:11 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。